Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

References

• Gupta SC, Sung B, Kim JH, et al. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res. 2013;57:1510–1528.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41:1955–1968.
   PubMed Web of Science ®Google Scholar
• Lu YP, Chang RL, Lou YR, et al. Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in JB6 cells and in mouse epidermis. Carcinogenesis. 1994;15:2363–2370.
   PubMed Web of Science ®Google Scholar
• Huang MT, Lou YR, Ma W, et al. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994;54:5841–5847.
   PubMed Web of Science ®Google Scholar
• Zhang C, Li B, Zhang X, et al. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients’ PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol. 2010;130:2110–2119.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Xu C, Keum Y-S, et al. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis. 2006;27:475–482.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–818.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847–6854.
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491–4499.
   PubMed Web of Science ®Google Scholar
• Tayyem RF, Heath DD, Al-Delaimy WK, et al. Curcumin content of turmeric and curry powders. Nutr Cancer. 2006;55:126–131.
   PubMed Web of Science ®Google Scholar
• Huang MT, Ma W, Lu YP, et al. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis. 1995;16:2493–2497.
   PubMed Web of Science ®Google Scholar
• Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28:1765–1773.
   PubMed Web of Science ®Google Scholar
• Yue GG, Cheng S-W, Yu H, et al. The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells. J Med Food. 2012;15:242–252.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim YH, Kim Y, et al. Aromatic-turmerone attenuates invasion and expression of MMP-9 and COX-2 through inhibition of NF-kappaB activation in TPA-induced breast cancer cells. J Cell Biochem. 2012;113:3653–3662.
   PubMed Web of Science ®Google Scholar
• Gopalan B, Goto M, Kodama A, et al. Supercritical carbon dioxide extraction of turmeric (Curcuma longa). J Agric Food Chem. 2000;48:2189–2192.
   PubMed Web of Science ®Google Scholar
• Singh G, Kapoor IP, Singh P, et al. Comparative study of chemical composition and antioxidant activity of fresh and dry rhizomes of turmeric (Curcuma longa Linn.). Food Chem Toxicol. 2010;48:1026–1031.
   PubMed Web of Science ®Google Scholar
• Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60:1620–1637.
   PubMed Web of Science ®Google Scholar
• Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1991;88:5292–5296.
   PubMed Web of Science ®Google Scholar
• Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999;18:6013–6020.
   PubMed Web of Science ®Google Scholar
• Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001;61:1058–1064.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.
   PubMed Web of Science ®Google Scholar
• Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10:8465–8471.
   PubMed Web of Science ®Google Scholar
• Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005;11:6738–6744.
   PubMed Web of Science ®Google Scholar
• Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res. 2001;480–481:243–268.
   PubMed Web of Science ®Google Scholar
• Sharma C, Kaur J, Shishodia S, et al. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology. 2006;228:1–15.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140:935–950.
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87:504–508.
   PubMed Web of Science ®Google Scholar
• Chua W, Clarke SJ, Charles KA. Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer. 2012;20:1869–1874.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–e503.
   PubMed Web of Science ®Google Scholar
• Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology. 2001;121:1339–1347.
   PubMed Web of Science ®Google Scholar
• Jiang MC, Yang-Yen HF, Yen JJ, et al. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996;26:111–120.
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505–516.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–1174.
   PubMed Web of Science ®Google Scholar
• Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006;25:278–287.
   PubMed Web of Science ®Google Scholar
• Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer. 2008;122:267–273.
   PubMed Web of Science ®Google Scholar
• Patel BB, Gupta D, Elliott AA, et al. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res. 2010;30:319–325.
   PubMed Web of Science ®Google Scholar
• Sun X-D, Liu X-E, Huang D-S. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep. 2012;6:1267–1270.
   PubMed Web of Science ®Google Scholar
• Boyanapalli SS, Tony Kong A-N. “Curcumin, the king of spices”: epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Curr Pharmacol Rep. 2015;1:129–139.
   PubMedGoogle Scholar
• Guo Y, Shu L, Zhang C, et al. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1. Biochem Pharmacol. 2015;94:69–78.
   PubMed Web of Science ®Google Scholar
• Sun M, Estrov Z, Ji Y, et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7:464–473.
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–2054.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xie Z, Jones W, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2009;19:706–709.
   PubMed Web of Science ®Google Scholar
• Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010;116:4670–4676.
   PubMed Web of Science ®Google Scholar
• Teiten M-H, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Mol Nutr Food Res. 2013;57:1619–1629.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Ebeling MC, Khan S, et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013;12:1471–1480.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Khan S, Maher DM, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014;35:8635–8648.
   PubMed Web of Science ®Google Scholar
• Zaman MS, Chauhan N, Yallapu MM, et al. Curcumin nanoformulation for cervical cancer treatment. Sci Rep. 2016;6:20051.
   PubMed Web of Science ®Google Scholar
• Lee W-H, Loo C-Y, Young PM, et al. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014;11:1183–1201.
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des. 2013;19:1994–2010.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–2900.
   PubMed Web of Science ®Google Scholar
• Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005;14:120–125.
   PubMed Web of Science ®Google Scholar
• He Z-Y, Shi C-B, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29:208–213.
   PubMed Web of Science ®Google Scholar
• Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90:1011–1015.
   PubMed Web of Science ®Google Scholar
• Klickovic U, Doberer D, Gouya G, et al. Human pharmacokinetics of high dose oral curcumin and its effect on heme oxygenase-1 expression in healthy male subjects. Biomed Res Int. 2014;2014:1–7.
   Web of Science ®Google Scholar
• Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002;244:127–135.
   PubMed Web of Science ®Google Scholar
• Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15:1867–1876.
   PubMed Web of Science ®Google Scholar
• Lin JK, Pan MH, Lin-Shiau SY. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors. 2000;13:153–158.
   PubMed Web of Science ®Google Scholar
• Dempe JS, Scheerle RK, Pfeiffer E, et al. Metabolism and permeability of curcumin in cultured Caco-2 cells. Mol Nutr Food Res. 2013;57:1543–1549.
   PubMed Web of Science ®Google Scholar
• Wahlang B, Pawar YB, Bansal AK. Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm. 2011;77:275–282.
   PubMed Web of Science ®Google Scholar
• Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol. 2008;76:1590–1611.
   PubMed Web of Science ®Google Scholar
• Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26:2039–2054.
   PubMed Web of Science ®Google Scholar
• Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica. 1978;8:761–768.
   PubMed Web of Science ®Google Scholar
• Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486–494.
   PubMed Web of Science ®Google Scholar
• Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002;11:105–111.
   PubMed Web of Science ®Google Scholar
• Marczylo TH, Verschoyle RD, Cooke DN, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 2007;60:171–177.
   PubMed Web of Science ®Google Scholar
• Hoehle SI, Pfeiffer E, Metzler M. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res. 2007;51:932–938.
   PubMed Web of Science ®Google Scholar
• Pfeiffer E, Hoehle SI, Walch SG, et al. Curcuminoids form reactive glucuronides in vitro. J Agric Food Chem. 2007;55:538–544.
   PubMed Web of Science ®Google Scholar
• Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci. 2000;67:2785–2793.
   PubMed Web of Science ®Google Scholar
• Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17:1411–1417.
   PubMed Web of Science ®Google Scholar
• Kanai M, Imaizumi A, Otsuka Y, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 2012;69:65–70.
   PubMed Web of Science ®Google Scholar
• Gota VS, Maru GB, Soni TG, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010;58:2095–2099.
   PubMed Web of Science ®Google Scholar
• Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7:1894–1900.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Furuie H, Inano A, et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol. 2012;166:1793–1803.
   PubMed Web of Science ®Google Scholar
• Lao CD, Ruffin M, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
   PubMedGoogle Scholar
• Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28:110–113.
   PubMed Web of Science ®Google Scholar
• Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68:157–164.
   PubMed Web of Science ®Google Scholar
• Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4:43.
   PubMed Web of Science ®Google Scholar
• Irving GR, Howells LM, Sale S, et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration–a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila). 2013;6:119–128.
   PubMed Web of Science ®Google Scholar
• Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011;4:354–364.
   PubMed Web of Science ®Google Scholar
• Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–356.
   PubMed Web of Science ®Google Scholar
• Volak LP, Hanley MJ, Masse G, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75:450–462.
   PubMed Web of Science ®Google Scholar
• Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14:141–153.
   PubMed Web of Science ®Google Scholar
• Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74:664–669.
   PubMed Web of Science ®Google Scholar
• Jäger R, Lowery RP, Calvanese AV, et al. Comparative absorption of curcumin formulations. Nutr J. 2014;13:11.
   PubMed Web of Science ®Google Scholar
• Asher GN, Xie Y, Moaddel R, et al. Randomized pharmacokinetic crossover study comparing 2 curcumin preparations in plasma and rectal tissue of healthy human volunteers. J Clin Pharmacol. 2017;57:185–193.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34:660–665.
   PubMed Web of Science ®Google Scholar
• Morimoto T, Sunagawa Y, Katanasaka Y, et al. Drinkable preparation of Theracurmin exhibits high absorption efficiency–a single-dose, double-blind, 4-way crossover study. Biol Pharm Bull. 2013;36:1708–1714.
   PubMed Web of Science ®Google Scholar
• Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 2013;71:1521–1530.
   PubMed Web of Science ®Google Scholar
• Sunagawa Y, Hirano S, Katanasaka Y, et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. J Nutr Sci Vitaminol (Tokyo). 2015;61:37–44.
   PubMed Web of Science ®Google Scholar
• Schiborr C, Kocher A, Behnam D, et al. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58:516–527.
   PubMed Web of Science ®Google Scholar
• Dützmann S, Schiborr C, Kocher A, et al. Intratumoral concentrations and effects of orally administered micellar curcuminoids in glioblastoma patients. Nutr Cancer. 2016;68:943–948.
   PubMed Web of Science ®Google Scholar
• Antony B, Merina B, Iyer VS, et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008;70:445–449.
   PubMed Web of Science ®Google Scholar
• Storka A, Vcelar B, Klickovic U, et al. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 2015;53:54–65.
   PubMed Web of Science ®Google Scholar
• Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60:717–733.
   PubMed Web of Science ®Google Scholar
• Chan MM, Huang HI, Fenton MR, et al. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol. 1998;55:1955–1962.
   PubMed Web of Science ®Google Scholar
• Gescher AJ. Dose escalation and pharmacokinetic study of nanoparticle curcumin… by Kanai et al., CCP 69:65-70, 2012. Cancer Chemother Pharmacol. 2012;70:487.
   PubMed Web of Science ®Google Scholar
• Pal A, Sung B, Bhanu Prasad BA, et al. Curcumin glucuronides: assessing the proliferative activity against human cell lines. Bioorg Med Chem. 2014;22:435–439.
   PubMed Web of Science ®Google Scholar
• Shoji M, Nakagawa K, Watanabe A, et al. Comparison of the effects of curcumin and curcumin glucuronide in human hepatocellular carcinoma HepG2 cells. Food Chem. 2014;151:126–132.
   PubMed Web of Science ®Google Scholar
• López-Lázaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat Prod. 2007;70:1884–1888.
   PubMed Web of Science ®Google Scholar
• Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol. 2015;29:642–651.
   PubMed Web of Science ®Google Scholar
• DiSilvestro RA, Joseph E, Zhao S, et al. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012;11:79.
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci. 2010;99:4630–4641.
   PubMed Web of Science ®Google Scholar
• Yan Y-D, Kim DH, Sung JH, et al. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm. 2010;399:116–120.
   PubMed Web of Science ®Google Scholar
• Lee C-K, Ki S-H, Choi J-S. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharm Drug Dispos. 2011;32:245–251.
   PubMed Web of Science ®Google Scholar
• Yan Y-D, Marasini N, Choi YK, et al. Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS). Eur J Drug Metab Pharmacokinet. 2012;37:217–224.
   PubMed Web of Science ®Google Scholar
• Sun X, Li J, Guo C, et al. Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s. Drug Metab Pharmacokinet. 2016;31:269–275.
   PubMed Web of Science ®Google Scholar
• Hsieh Y-W, Huang C-Y, Yang S-Y, et al. Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies. Sci Rep. 2014;4:6587.
   PubMed Web of Science ®Google Scholar
• Zhang W, Tan TM, Lim L-Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos. 2007;35:110–115.
   PubMed Web of Science ®Google Scholar
• Shukla S, Zaher H, Hartz A, et al. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009;26:480–487.
   PubMed Web of Science ®Google Scholar
• Pavithra BH, Prakash N, Jayakumar K. Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. J Vet Sci. 2009;10:293–297.
   PubMed Web of Science ®Google Scholar
• Liu A-C, Zhao L-X, Xing J, et al. Pre-treatment with curcumin enhances plasma concentrations of losartan and its metabolite EXP3174 in rats. Biol Pharm Bull. 2012;35:145–150.
   PubMed Web of Science ®Google Scholar
• Cheng K-W, Wong CC, Mattheolabakis G, et al. Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics. Int J Oncol. 2013;43:895–902.
   PubMed Web of Science ®Google Scholar
• Egashira K, Sasaki H, Higuchi S, et al. Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet. 2012;27:242–247.
   PubMed Web of Science ®Google Scholar
• Vatsavai LK, Kilari EK. Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models. J Exp Pharmacol. 2016;8:69–76.
   PubMedGoogle Scholar
• Liu A-C, Zhao L-X, Lou H-X. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregation. Planta Med. 2013;79:971–977.
   PubMed Web of Science ®Google Scholar
• Kim S-A, Kim S-W, Choi H-K, et al. Enhanced systemic exposure of saquinavir via the concomitant use of curcumin-loaded solid dispersion in rats. Eur J Pharm Sci. 2013;49:800–804.
   PubMed Web of Science ®Google Scholar
• Ge S, Yin T, Xu B, et al. Curcumin affects phase II disposition of resveratrol through inhibiting efflux transporters MRP2 and BCRP. Pharm Res. 2016;33:590–602.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang F, Chen C, et al. Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. Xenobiotica. 2017;47:267–275.
   Web of Science ®Google Scholar
• Juan H, Terhaag B, Cong Z, et al. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol. 2007;63:663–668.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu W-H, Chen B-L, et al. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother. 2010;44:1038–1045.
   PubMed Web of Science ®Google Scholar
• Al-Jenoobi FI, Al-Thukair AA, Alam MA, et al. Effect of Curcuma longa on CYP2D6- and CYP3A4-mediated metabolism of dextromethorphan in human liver microsomes and healthy human subjects. Eur J Drug Metab Pharmacokinet. 2015;40:61–66.
   PubMed Web of Science ®Google Scholar
• He X, Mo L, Li Z-Y, et al. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. Xenobiotica. 2012;42:1248–1254.
   PubMed Web of Science ®Google Scholar
• Zhang W, Lim L-Y. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos. 2008;36:1283–1290.
   PubMed Web of Science ®Google Scholar
• Ampasavate C, Sotanaphun U, Phattanawasin P, et al. Effects of Curcuma spp. on P-glycoprotein function. Phytomedicine. 2010;17:506–512.
   PubMed Web of Science ®Google Scholar
• Jouan E, Le Vée M, Mayati A, et al. Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay. Pharmaceutics. 2016;8:12.
   PubMedGoogle Scholar
• Romiti N, Tongiani R, Cervelli F, et al. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci. 1998;62:2349–2358.
   PubMed Web of Science ®Google Scholar
• Anuchapreeda S, Leechanachai P, Smith MM, et al. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol. 2002;64:573–582.
   PubMed Web of Science ®Google Scholar
• Chearwae W, Anuchapreeda S, Nandigama K, et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem Pharmacol. 2004;68:2043–2052.
   PubMed Web of Science ®Google Scholar
• Tang X-Q, Bi H, Feng J-Q, et al. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005;26:1009–1016.
   PubMed Web of Science ®Google Scholar
• Neerati P, Sudhakar YA, Kanwar JR. Curcumin regulates colon cancer by inhibiting P-glycoprotein in in-situ cancerous colon perfusion rat model. J Cancer Sci Ther. 2013;5:313–319.
   PubMedGoogle Scholar
• Chearwae W, Shukla S, Limtrakul P, et al. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther. 2006;5:1995–2006.
   PubMed Web of Science ®Google Scholar
• Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989;36:89–96.
   PubMed Web of Science ®Google Scholar
• Fisher JM, Wrighton SA, Watkins PB, et al. First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther. 1999;289:1134–1142.
   PubMed Web of Science ®Google Scholar
• Chearwae W, Wu C-P, Chu H-Y, et al. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol. 2006;57:376–388.
   PubMed Web of Science ®Google Scholar
• Li L, Ahmed B, Mehta K, et al. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther. 2007;6:1276–1282.
   PubMed Web of Science ®Google Scholar
• Yue GG, Kwok HF, Lee JK, et al. Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice. Pharmacol Res. 2016;111:43–57.
   PubMed Web of Science ®Google Scholar
• Sung B, Kunnumakkara AB, Sethi G, et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009;8:959–970.
   PubMed Web of Science ®Google Scholar
• Zhu DJ, Huang YF, Chen XW, et al. Curcumin partly ameliorates irinotecan-induced diarrhea and synergistically promotes apoptosis in colorectal cancer through mediating oxidative stress. Oncotarget. 2016.DOI:https://doi.org/10.18632/oncotarget.10604
   Google Scholar
• Ghalaut VS, Sangwan L, Dahiya K, et al. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract. 2012;18:186–190.
   PubMedGoogle Scholar
• Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010;9:8–14.
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62:1137–1141.
   PubMed Web of Science ®Google Scholar
• James MI, Iwuji C, Irving G, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett. 2015;364:135–141.
   PubMed Web of Science ®Google Scholar
• Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1444.e1–1449.e1.
   PubMed Web of Science ®Google Scholar
• Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26:1719–1725.
   PubMed Web of Science ®Google Scholar
• Neerati P, Devde R, Gangi AK. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. Phytother Res. 2014;28:1796–1800.
   PubMed Web of Science ®Google Scholar
• Lee CA, O’Connor MA, Ritchie TK, et al. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metab Dispos. 2015;43:490–509.
   PubMed Web of Science ®Google Scholar
• Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev. 2010;30:818–860.
   PubMed Web of Science ®Google Scholar
• Irving GR, Iwuji CO, Morgan B, et al. Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials. 2015;16:110.
   PubMed Web of Science ®Google Scholar
• Gescher A. Editorial: curcumin: recent insights,novel developments, new challenges. Mol Nutr Food Res. 2013;57:1509.
   PubMed Web of Science ®Google Scholar
• Gosangari SL, Watkin KL. Effect of preparation techniques on the properties of curcumin liposomes: characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line. Pharm Dev Technol. 2012;17:103–109.
   PubMed Web of Science ®Google Scholar